Search | IOVS | ARVO Journals

Showing 1 – 20 of 23

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Practitioners’ perspectives on Demodex blepharitis: a comparison between eye care practitioners in India and Australasia

Nikhil Sharma; Eilidh Martin; Ian Pearce; Suzanne Hagan; Jennifer P Craig

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3945 – A0225. doi:

ARVO Annual Meeting Abstract June 2021

Proposing a Neurotropic Etiology for Acute Posterior Multifocal Placoid Pigment Epitheliopathy and Relentless Placoid Choroidopathy

Paul James Steptoe; Ian Pearce; Nicholas A V Beare; Sreekanth Sreekantam; Bashar R Mohammed; Robert Barry; Laura R Steeples; Alastair K Denniston

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3447. doi:

Articles April 2021

Predictive Association of Pre-Operative Defect Areas in the Outer Retinal Layers With Visual Acuity in Macular Hole Surgery

PDF

Carmen Baumann; Danilo Iannetta; Ziyaad Sultan; Ian A. Pearce; Chris P. Lohmann; Yalin Zheng; Stephen B. Kaye
TAGS: embryonic lethal mutation, repair of hole of macula lutea, visual acuity, postoperative care
Trans. Vis. Sci. Tech.. 2021; 10(4):7. doi: https://doi.org/10.1167/tvst.10.4.7

ARVO Annual Meeting Abstract July 2019

Effectiveness of 3% trehalose and 0.15% sodium hyaluronate eye drop in an adverse dry environment

Hamad Alzamil; Louise; Madden; Edward Ian Pearce

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):304. doi:

ARVO Annual Meeting Abstract July 2019

Does inducing tear hyperosmolarity cause a change in inflammatory marker levels?

Edward Ian Pearce; Reem Almutairi; Saleh Alshammari; Suzanne Hagan; Louise; Madden

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4183. doi:

ARVO Annual Meeting Abstract July 2019

Acceptability of OCT Angiography: A multicentre OCT Angiography NEtwork (OCTANE) study.

Faruque Ghanchi; Corinne Fulcher; Sobha Sivaprasad; Konstantinos Balaskas; Richard Peter Gale; Gabriella De Salvo; James S Talks; Andrew Lotery; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3477. doi:

ARVO Annual Meeting Abstract July 2019

Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy

Zhihang Cheng; Salma Babiker; Pauline Lenfestey; Nick Beare; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5002. doi:

ARVO Annual Meeting Abstract July 2018

Real-world outcomes of ranibizumab in patients with retinal vein occlusion from the LUMINOUS™ study

Ian Pearce; Soumil Parikh; Wayne Macfadden

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2566. doi:

ARVO Annual Meeting Abstract June 2017

Validating strip meniscometry tube (SMTube) as a method for measuring tear production in the diagnosis of aqueous deficient dry eye (ADDE)

Saleh Alshammeri; Suzanne Hagan; Louise Madden; Ian Pearce

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2666. doi:

ARVO Annual Meeting Abstract June 2017

Clinical characteristics and treatment outcomes in Central Serous Chorioretinopathy with secondary choroidal neovascularisation.

Danilo Iannetta; Savitha Madhusudhan; Nicholas V Beare; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2315. doi:

ARVO Annual Meeting Abstract September 2016

Efficacy of anti-tumor necrosis factor (anti-TNF) treatment in a tertiary uveitis service in the United Kingdom

Paul J Steptoe; Deborah Broadbent; Amira Stylianides; Nick Beare; Devesh Mewar; Ian Pearce

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1882. doi:

ARVO Annual Meeting Abstract September 2016

Real-world outcomes of ranibizumab treatment in patients with retinal vein occlusion: the LUMINOUS™ study

Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5155. doi:

ARVO Annual Meeting Abstract September 2016

Grading OCT characteristics did not clearly predict treatment outcomes in the RELIGHT study participants

Tunde Peto; Usha Chakravarthy; Susanne Lupton; Kara Gibson; James Warburton; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2084. doi:

ARVO Annual Meeting Abstract June 2015

One-year outcomes of ranibizumab treatment in a cohort of patients with retinal vein occlusion: an interim analysis from the real-world LUMINOUS study

Ian A Pearce; Ayan Das Gupta; Sue Lacey; LUMINOUS

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3743. doi:

ARVO Annual Meeting Abstract April 2014

Effect of Three Tear Supplements on Signs, Symptoms and Pro-Inflammatory Markers in Subjects with Dry Eye Disease

Eilidh Martin; Suzanne Hagan; Katherine Oliver; Ian Pearce; Alan Tomlinson

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3669. doi:

ARVO Annual Meeting Abstract April 2014

Ranibizumab treatment of diabetic macular edema with bimonthly monitoring: 18-month outcomes of the Phase IIIb multicenter RELIGHT study

Ian A Pearce; RELIGHT study group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1701. doi:

ARVO Annual Meeting Abstract April 2014

Use of dexamethasone implant for refractory CME secondary to uveitis

Nikolaos Krassas; Natasha Spiteri; Nicholas Beare; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5308. doi:

ARVO Annual Meeting Abstract April 2014

Efficacy and safety of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion: Design and baseline characteristics of the CRYSTAL study

Francesco Boscia; Heinrich Gerding; Ian A Pearce; Siegfried Priglinger; Ramin Tadayoni; Jackie Han; George Lambrou; William John Stubbings; Jordi M Mones

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):606. doi:

ARVO Annual Meeting Abstract April 2014

Ranibizumab ±adjunctive laser vs laser in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO): Design and baseline characteristics of the BRIGHTER study

Heinrich Gerding; Francesco Boscia; Jordi M Mones; Siegfried Priglinger; Ramin Tadayoni; Jackie Han; George Lambrou; William John Stubbings; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):607. doi:

ARVO Annual Meeting Abstract June 2013

RELIGHT - Ranibizumab treatment of diabetic macular oedema with bimonthly monitoring after a phase of initial Treatment

Ian Pearce; RELIGHT STUDY GROUP

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4029. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Practitioners’ perspectives on Demodex blepharitis: a comparison between eye care practitioners in India and Australasia

Proposing a Neurotropic Etiology for Acute Posterior Multifocal Placoid Pigment Epitheliopathy and Relentless Placoid Choroidopathy

Predictive Association of Pre-Operative Defect Areas in the Outer Retinal Layers With Visual Acuity in Macular Hole Surgery

Effectiveness of 3% trehalose and 0.15% sodium hyaluronate eye drop in an adverse dry environment

Does inducing tear hyperosmolarity cause a change in inflammatory marker levels?

Acceptability of OCT Angiography: A multicentre OCT Angiography NEtwork (OCTANE) study.

Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy

Real-world outcomes of ranibizumab in patients with retinal vein occlusion from the LUMINOUS™ study

Validating strip meniscometry tube (SMTube) as a method for measuring tear production in the diagnosis of aqueous deficient dry eye (ADDE)

Clinical characteristics and treatment outcomes in Central Serous Chorioretinopathy with secondary choroidal neovascularisation.

Efficacy of anti-tumor necrosis factor (anti-TNF) treatment in a tertiary uveitis service in the United Kingdom

Real-world outcomes of ranibizumab treatment in patients with retinal vein occlusion: the LUMINOUS™ study

Grading OCT characteristics did not clearly predict treatment outcomes in the RELIGHT study participants

One-year outcomes of ranibizumab treatment in a cohort of patients with retinal vein occlusion: an interim analysis from the real-world LUMINOUS study

Effect of Three Tear Supplements on Signs, Symptoms and Pro-Inflammatory Markers in Subjects with Dry Eye Disease

Ranibizumab treatment of diabetic macular edema with bimonthly monitoring: 18-month outcomes of the Phase IIIb multicenter RELIGHT study

Use of dexamethasone implant for refractory CME secondary to uveitis

Efficacy and safety of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion: Design and baseline characteristics of the CRYSTAL study

Ranibizumab ±adjunctive laser vs laser in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO): Design and baseline characteristics of the BRIGHTER study

RELIGHT - Ranibizumab treatment of diabetic macular oedema with bimonthly monitoring after a phase of initial Treatment

To View More...

You must be signed into an individual account to use this feature.